

## Original Investigation

# Association Between Participation in a Multipayer Medical Home Intervention and Changes in Quality, Utilization, and Costs of Care

Mark W. Friedberg, MD, MPP; Eric C. Schneider, MD, MSc; Meredith B. Rosenthal, PhD; Kevin G. Volpp, MD, PhD; Rachel M. Werner, MD, PhD

**IMPORTANCE** Interventions to transform primary care practices into medical homes are increasingly common, but their effectiveness in improving quality and containing costs is unclear.

**OBJECTIVE** To measure associations between participation in the Southeastern Pennsylvania Chronic Care Initiative, one of the earliest and largest multipayer medical home pilots conducted in the United States, and changes in the quality, utilization, and costs of care.

**DESIGN, SETTING, AND PARTICIPANTS** Thirty-two volunteering primary care practices participated in the pilot (conducted from June 1, 2008, to May 31, 2011). We surveyed pilot practices to compare their structural capabilities at the pilot's beginning and end. Using claims data from 4 participating health plans, we compared changes (in each year, relative to before the intervention) in the quality, utilization, and costs of care delivered to 64 243 patients who were attributed to pilot practices and 55 959 patients attributed to 29 comparison practices (selected for size, specialty, and location similar to pilot practices) using a difference-in-differences design.

**EXPOSURES** Pilot practices received disease registries and technical assistance and could earn bonus payments for achieving patient-centered medical home recognition by the National Committee for Quality Assurance (NCQA).

**MAIN OUTCOMES AND MEASURES** Practice structural capabilities; performance on 11 quality measures for diabetes, asthma, and preventive care; utilization of hospital, emergency department, and ambulatory care; standardized costs of care.

**RESULTS** Pilot practices successfully achieved NCQA recognition and adopted new structural capabilities such as registries to identify patients overdue for chronic disease services. Pilot participation was associated with statistically significantly greater performance improvement, relative to comparison practices, on 1 of 11 investigated quality measures: nephropathy screening in diabetes (adjusted performance of 82.7% vs 71.7% by year 3,  $P < .001$ ). Pilot participation was not associated with statistically significant changes in utilization or costs of care. Pilot practices accumulated average bonuses of \$92 000 per primary care physician during the 3-year intervention.

**CONCLUSIONS AND RELEVANCE** A multipayer medical home pilot, in which participating practices adopted new structural capabilities and received NCQA certification, was associated with limited improvements in quality and was not associated with reductions in utilization of hospital, emergency department, or ambulatory care services or total costs over 3 years. These findings suggest that medical home interventions may need further refinement.

JAMA. 2014;311(8):815-825. doi:10.1001/jama.2014.353

← Editorial page 802

+ Author Video Interview at [jama.com](http://jama.com)

+ Supplemental content at [jama.com](http://jama.com)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Mark W. Friedberg, MD, MPP, 20 Park Plaza, Ste 920, Boston, MA 02116 (mfriedbe@rand.org).

Professional associations, payers, policy makers, and other stakeholders have advocated the patient-centered medical home, a team-based model of primary care practice intended to improve the quality, efficiency, and patient experience of care.<sup>1,2</sup> In general, medical home initiatives have encouraged primary care practices to invest in patient registries, enhanced access options, and other structural capabilities in exchange for enhanced payments—often operationalized as per-patient per-month fees for comprehensive care services.<sup>3,4</sup> Dozens of privately and publicly financed medical home pilots are under way, and most use recognition by the National Committee for Quality Assurance (NCQA) to assess practice structural capabilities.<sup>4,5</sup>

Recent evidence reviews suggest that early “medical home” interventions have yielded modest improvements at best in quality and patient experience, with little evidence of effects on costs of care.<sup>6–8</sup> However, these reviews included studies that preceded development of NCQA medical home recognition criteria and lacked significant financial support from payers, potentially limiting their applicability to current medical home efforts.<sup>9,10</sup> More recent evaluations have assessed medical home pilots including only 1 payer (potentially a small fraction of some practices’ patient panels) occurring over a 1- or 2-year time frame (possibly insufficient to observe effects requiring longer time frames),<sup>11–13</sup> or within large, integrated delivery systems atypical of most primary care practices.<sup>14,15</sup> We hypothesized that a multipayer medical home initiative involving a longer intervention period and substantial financial support would be more likely to be associated with measurable improvements in quality and efficiency.

## Methods

We evaluated associations between implementation of the Pennsylvania Chronic Care Initiative (PACCI), a statewide multipayer medical home pilot, and changes in the quality, utilization, and cost of care. This study was approved by the RAND human subjects protection committee and the University of Pennsylvania institutional review board, with implied informed consent for practice structural surveys and waived consent for analyses of deidentified claims data.

### Pilot Design

The pilot was initiated in Pennsylvania’s southeast region among volunteering small- and medium-sized primary care practices from June 1, 2008, to May 31, 2011. As detailed elsewhere,<sup>16,17</sup> the PACCI was designed by a coalition of payers, clinicians, and delivery systems led by the Governor’s Office of Health Care Reform and implemented as a series of regional medical home pilots, beginning with the southeast region.

Practices in southeast Pennsylvania were invited to participate by the 6 health plans (3 commercial and 3 Medicaid managed care plans) and 3 professional organizations (the Pennsylvania Academy of Family Physicians, American Col-

lege of Physicians, and American Academy of Pediatrics) participating in the PACCI, with the goal of enrolling a mix of practice sizes and specialties (family practice, internal medicine, pediatric, and nurse-managed health centers).

The intervention consisted of technical assistance including a Breakthrough Series Learning Collaborative,<sup>18</sup> web-based Improving Performance in Practice (IPIP) disease registries to create monthly quality indicator reports,<sup>19</sup> and assistance from IPIP practice coaches to facilitate practice transformation and achievement of NCQA Physician Practice Connections–Patient-Centered Medical Home (PPC-PCMH) recognition (with level 1 recognition required by the second pilot year).<sup>20</sup> Performance improvement efforts targeted asthma for pediatric practices and diabetes for practices serving adults.

To support and motivate these improvements, each participating practice was eligible to receive a \$20 000 “practice support” payment in year 1 and annual bonus payments per full-time equivalent clinician (ie, per physician or nurse practitioner) that varied based on NCQA medical home recognition level and practice size, ranging from \$28 000 per clinician in NCQA level 1 practices with 10 to 20 clinicians to \$95 000 per clinician in solo NCQA level 3 practices.

### Comparison Practices

Within 3 months of recruiting pilot practices, the state selected comparison practices. To do this, a state contractor obtained lists of candidate practices from participating health plans and, without performing a strict 1-to-1 match, identified a group of comparison practices that had the same approximate composition as the pilot practices in practice size, specialty (pediatrics, family practice, internal medicine), location (urban, suburban), and affiliation with local health systems. Data on quality, utilization, and costs were unavailable for comparison practice selection.

### Pilot Data, Practice Survey, and Claims Data

We obtained, from Pennsylvania’s demonstration conveners, annual data on each pilot practice’s level of NCQA PPC-PCMH recognition (none or level 1, 2, or 3) and amounts of each pilot practice’s bonus payments.

Drawing from a survey instrument designed to assess practice readiness for the medical home,<sup>21</sup> we devised a new survey to measure practices’ structural capabilities, including presence of performance feedback, disease management, registries, reminder and outreach systems for patients with chronic disease, and electronic health records (EHRs) (instrument available from authors on request).

We fielded the practice survey twice to each pilot and comparison practice: a “baseline” survey in September 2010, querying capabilities just prior to June 2008 (the pilot’s beginning), and a final survey in June 2011, querying capabilities at the pilot’s end. We addressed each survey to 1 leader per practice, identified by telephone call, who could report accurately on the practice’s structural capabilities.

We requested from each of the 6 participating health plans all medical and prescription drug claims and enrollment data spanning June 1, 2006, to May 30, 2011 (2 years prior to and 3

years after the pilot inception date of June 1, 2008), for their members who, at any time during this 5-year period, had 1 or more medical claims (for any service) with a pilot or comparison practice.

### Patient Attribution

In each of 4 time periods (the preintervention period and intervention years 1, 2, and 3), we attributed patients to the primary care clinicians (specialty designations family practice, general practice, internal medicine, pediatrics, adolescent medicine, geriatric medicine, and nurse practitioner) who provided the plurality of qualifying services (*Current Procedural Terminology* codes 9920x, 9921x, 9924x, 99381-99387, 99391-99397, 99401-99404, 99411-99412, 99420-99429, 99339-99340, 99341-99345, 99347-99350, G0402, G0438, G0439), with the most recent service breaking ties. In sensitivity analyses, we reattributed patients based on the majority (>50%) of qualifying services.

### Measures of Quality, Utilization, and Costs

We calculated claims-based process measures of quality using NCQA Healthcare Effectiveness and Data Information Set (HEDIS) specifications, following published recommendations<sup>22</sup> and making adjustments as necessary to account for the limited available look-back period. Using laboratory data available from one commercial health plan, we also calculated 2 measures of diabetes control, also based on HEDIS specifications.

To measure utilization, we calculated rates of hospitalization (all-cause), emergency department (ED) visits (all-cause), and ambulatory visits following published recommendations.<sup>23</sup> We also calculated rates of ambulatory care-sensitive hospitalizations and ED visits, because these may be more likely to represent avoidable (and potentially wasteful) resource utilization, relative to all-cause hospitalizations and ED visits. Because health care prices can be sensitive to local market factors, we calculated standardized prices for all claims using Optum normalized pricing software.<sup>24</sup> The eAppendix in the Supplement presents measure specifications.

### Statistical Analyses

We compared pilot and comparison practices and their preintervention patient populations using Wilcoxon rank sum and Fisher exact tests. To characterize pilot practices' adoption of structural capabilities, we compared baseline and postintervention rates of capability possession (eg, rates at which practices had EHRs) using Liddell exact tests to account for repeated measurements, excluding 3 practices that did not respond to both surveys.

To mitigate the potential influence of patient selection (which could in theory be induced by pilot participation), in our main analyses we assigned patients to practices based on preintervention attribution only. Under this intent-to-treat framework, any patients switching their primary care physicians (ie, becoming attributed to another practice) during the intervention would still be attributed to their preintervention practices for analysis. Two potential drawbacks of prein-

tervention attribution are nondetectability of interventions targeting patients new to a practice (eg, enhanced patient intake procedures) and potential confounding by time-varying patterns of health care consumption.<sup>25</sup> Therefore, we performed sensitivity analyses using sequential cross-sectional attribution (ie, reattributing patients in each year based on their visits in that year) to assign patients.

To evaluate associations between the PACCI intervention and changes in quality measure performance, we fit generalized logistic models using propensity weights to balance pilot and comparison practices' shares of patients from each health plan and baseline performance on each measure. By giving more weight to observations from comparison practices whose baseline performance resembled that of pilot practices, this weighting method produced "average treatment effect on the treated" (ATT) estimates, answering the question: "Among practices closely resembling the pilot practices, what changes are associated with the intervention?"<sup>26</sup> The dependent variable in each model was patient-level receipt of the indicated service, and independent variables were indicators for time period (preintervention and each intervention year), interactions between time period and pilot/comparison status, indicators for the health plan contributing each observation and patient enrollment in a health maintenance organization (HMO), and fixed effects (dummy variables) for each practice.

For measures of utilization, we fit negative binomial models, using ATT propensity weighting to balance health plans and baseline utilization rates. The dependent variable in each model was the utilization count in the time period of interest. Independent variables were indicators for time period (preintervention and each intervention year); interaction between time period and pilot/comparison status; indicators for the health plan contributing each observation and patient enrollment in an HMO; patient age, sex, and preintervention Charlson comorbidity score<sup>27</sup>; and practice fixed effects. In sensitivity analyses, we refit the utilization models using 2-part models (logistic and negative binomial).

For measures of cost, we fit propensity-weighted models with the same independent variables but used a linear functional form, following the methods of recent similar evaluations.<sup>28</sup> In sensitivity analyses, we refit the cost models using log-transformed costs.<sup>29</sup>

We also identified patients who had multiple all-cause hospitalizations or ED visits (2 visits or  $\geq 3$  visits) within a single year. We then fit logistic models to identify pilot-associated changes in the prevalence of these "multiple use" patients, using the same independent variables as the other utilization models.

In all models, we used generalized estimating equations with robust standard errors to account for heteroscedasticity, autocorrelation, and clustering of patients within practices.<sup>30,31</sup> Because these methods can be sensitive to missing data, which are created when patients change health plans, we included only health plan members who were continuously enrolled during the study period in our main models. However, because of small numbers of patients contributing observations for hemoglobin A<sub>1c</sub> and low-density lipoprotein cholesterol con-

Table 1. Baseline Characteristics of Pilot and Comparison Practices

	Pilot (32 Practices, 64 243 Attributed Patients)	Comparison (29 Practices, 55 959 Attributed Patients)	P Value <sup>a</sup>
No. of PCPs, median (IQR)	5 (4-6)	4 (3-8)	.99
Main specialty, No.			
Family practice	16	16	.91
Internal medicine	9	7	
Pediatrics	7	6	
Location, No.			
Urban	30	27	.99
Suburban	2	2	
Nurse-managed health center, No.	6 <sup>b</sup>	0	.03
Patient panel characteristics, median (IQR) <sup>c</sup>			
No. of attributed patients per practice	1245 (481-2245)	1291 (875-2471)	.70
Female sex, %	58 (50-68)	52 (50-59)	.15
Age among adults, y	44 (30-57)	44 (28-56)	.54
Diabetes, %	7 (5-9)	6 (3-9)	.51
Asthma, %	2 (1-4)	2 (1-4)	.89
Practice Charlson score, mean (IQR)	1.00 (0.71-1.42)	1.02 (0.49-1.48)	.77
Insurance type, median (IQR), %			
Commercially insured, %	65 (27-98)	39 (19-98)	.94
Health plan A, commercial	18 (6-51)	13 (3-32)	.14
Health plan B, commercial	28 (11-45)	25 (8-71)	.64
Health plan C, Medicaid	23 (2-61)	33 (2-73)	.82
Health plan D, Medicaid <sup>d</sup>	0 (0-74)	0 (0-90)	.75

Abbreviations: IQR, interquartile range; PCP, primary care physician or clinician (including MDs, DOs, and nurse practitioners).

<sup>a</sup> Wilcoxon rank sum test for counts, percentages, and other continuous variables; Pearson  $\chi^2$  and Fisher exact tests for categorical variables. Note: all variables are calculated at the practice level.

<sup>b</sup> Five of the nurse-managed health centers had patient panels resembling family practices (22%-52% pediatric); the sixth had no pediatric patients.

<sup>c</sup> Calculated at the practice level among patients attributed to study practices in the preintervention period based on plurality of qualifying visits.

<sup>d</sup> Minimum-maximum reported rather than IQR because the IQR is (0-0).

trol and pediatric asthma controller medication use, models for these measures included patients lacking continuous enrollment.

To display adjusted performance data, we used recycled prediction methods, which allow estimates of associations on the original scale of the data, accounting for differences in covariate patterns between pilot and comparison practices.<sup>32,33</sup>

We conducted sensitivity analyses in addition to those described herein. We repeated our analyses using a plan-by-plan basis, excluding nurse-managed health centers (because no comparison practices were in this category), and including health plan members who were not continuously enrolled during the study period. Because reductions in utilization and costs of care might be more achievable and detectable among patients with chronic illness and diabetes was targeted by the PACCI, we repeated our utilization and cost models among only patients with diabetes.<sup>34</sup>

We considered 2-tailed *P* values <.05 significant. We performed data management and analyses using SAS version 9.2 (SAS Institute), SQL Server 2008 (Microsoft), and R version 3.0.0 (R Foundation).

## Results

All 34 volunteering practices were admitted to the pilot, but 2 withdrew prior to its initiation (ie, before receiving any assis-

tance or supplemental funding) for reasons unrelated to the pilot (office manager illness in 1 practice and key staff member departure in the other). All 32 remaining practices completed the pilot; none dropped out. The 6 participating health plans together accounted for the majority of total revenues (median, 65%) among pilot practices.

The 32 pilot and 29 comparison practices were similar in baseline size, specialty, and patient case mix (Table 1). However, 6 pilot practices were nurse-managed health centers, whereas no comparison practices were. In total, 64 243 patients were attributed to pilot practices and 55 959 to comparison practices in the preintervention period.

Twenty-nine pilot practices (91%) completed both the baseline and year 3 structural surveys. A low survey response rate (24%) among comparison practices precluded meaningful analysis of comparison practices' structural capabilities.

All of the pilot practices achieved NCQA PPC-PCMH recognition by the third intervention year, with half achieving level 3 status (Table 2). Pilot practices accumulated average bonuses of \$92 000 per primary care physician and reported structural transformation on a wide range of capabilities. For example, use of registries to identify patients overdue for chronic disease services increased from 30% to 85% of pilot practices (*P* < .001), and electronic medication prescribing increased from 38% to 86% (*P* = .001).

Four of the 6 health plans (the largest 2 commercial and largest 2 Medicaid plans) supplied claims data. One of these 4 plans was unable to supply claims dated prior to

Table 2. NCQA Recognition, Financial Bonuses, and Selected Structural Changes Among Pilot Practices

	No. of Practices Contributing Data	Baseline, No. (%) of Practices <sup>a</sup>	Pilot Year 3, No. (%)	P Value <sup>b</sup>
NCQA recognition level				
1	32	NA <sup>c</sup>	13 (41)	NA
2	32	NA	3 (9)	NA
3	32	NA	16 (50)	NA
Financial bonus per PCP, mean (range)	32	NA <sup>d</sup>	\$92 000 (\$19 000-\$164 000)	NA
Performance feedback				
Quality feedback to PCPs	29	9 (31)	23 (79)	<.001
Utilization or cost feedback to PCPs	29	11 (38)	15 (52)	.22
Monthly or more frequent meetings about quality	29	8 (28)	21 (72)	<.001
Monthly or more frequent meetings about utilization	28	8 (29)	11 (39)	.55
Use of registry for patients				
Overdue for screening services	26	9 (35)	16 (62)	.07
Overdue for chronic disease services	27	8 (30)	23 (85)	<.001
Out of target range for chronic disease laboratory values	26	5 (19)	18 (69)	.001
At high risk of disease complications or hospitalization	29	3 (10)	27 (93)	<.001
Care management for patients				
At high risk of disease complications or hospitalization	29	3 (10)	27 (93)	<.001
Help in better managing their diabetes <sup>e</sup>	24	14 (58)	23 (96)	.004
Help in better managing their asthma <sup>e</sup>	28	14 (50)	21 (75)	.09
Routine assessment of self-management needs in chronic illness	28	3 (11)	16 (57)	.001
Referral system for linking to community programs	29	16 (55)	22 (76)	.11
Outreach systems to contact patients due for services				
Breast cancer screen	23	6 (26)	16 (70)	.002
Cervical cancer screen	23	7 (30)	13 (57)	.07
Colorectal cancer screen	23	5 (22)	14 (61)	.01
Diabetes: hemoglobin A <sub>1c</sub> test	24	6 (25)	19 (79)	<.001
Diabetes: cholesterol test	24	6 (25)	19 (79)	<.001
Diabetes: eye examination	24	5 (21)	18 (75)	<.001
Diabetes: nephropathy monitoring	24	5 (21)	17 (74)	<.001
After hospitalization	29	6 (21)	27 (93)	<.001
No appointment for extended period <sup>f</sup>	29	13 (45)	21 (72)	.06
EHR capabilities				
Patient medication lists	29	17 (59)	27 (93)	.002
Patient problem lists	29	17 (59)	26 (90)	.004
Consultation notes from specialists	29	15 (52)	22 (76)	.02
Hospital discharge summaries	29	17 (59)	22 (76)	.13
Electronic medication prescribing	29	11 (38)	25 (86)	.001
Electronic laboratory test ordering	29	10 (34)	23 (79)	<.001
Electronic radiology test ordering	28	7 (25)	11 (39)	.22
Alerts if ordered tests are not performed	27	6 (22)	11 (41)	.18
Secure messaging to and from patients	29	4 (14)	13 (45)	.004
Access				
Weekend care offered regularly	29	18 (62)	20 (69)	.63
Evening care offered ≥2 nights per wk	29	20 (69)	21 (72)	.99
Appointments for new patients within 2 wk	28	13 (46)	20 (71)	.04

Abbreviations: EHR, electronic health record; NA, not applicable; NCQA, National Committee for Quality Assurance; PCP, primary care physician or clinician (including MDs, DOs, and nurse practitioners).

<sup>a</sup> Because of item nonresponse, denominators for percentages are not the same for all entries in the table.

<sup>b</sup> Liddell exact test.

<sup>c</sup> No practice had submitted an NCQA recognition application at baseline (ie, prior to the start of the pilot).

<sup>d</sup> Cumulative over the 3-year pilot and calculable only in pilot year 3.

<sup>e</sup> Provided by specially trained nonphysician staff.

<sup>f</sup> Longer than clinically appropriate.

Table 3. Propensity-Weighted, Adjusted Quality-of-Care Differences Between Pilot and Comparison Practices Among Continuously Enrolled Patients

	No. of Eligible Patients	No. (%) <sup>a</sup>			
		Preintervention	Year 1	Year 2	Year 3
HbA <sub>1c</sub> testing					
Pilot	1079	919 (85.2)	920 (85.3)	952 (88.2)	950 (88.0)
Comparison	606	516 (85.2)	534 (88.2)	528 (87.1)	502 (82.8)
% Difference (95% CI)		NA <sup>b</sup>	-3.0 (-8.5 to 2.5)	1.1 (-5.8 to 8.0)	5.2 (-0.8 to 11.2)
P value		NA	.29	.75	.09
HbA <sub>1c</sub> abnormal					
Pilot	582	112 (19.2)	105 (18.1)	119 (20.4)	104 (17.9)
Comparison	175	34 (19.2)	26 (14.8)	26 (14.7)	18 (10.3)
% Difference (95% CI)		NA	3.3 (-6.6 to 13.2)	5.6 (-4.8 to 16.1)	7.5 (-1.4 to 16.4)
P value		NA	.51	.29	.10
LDL-C testing					
Pilot	1079	880 (81.6)	878 (81.4)	905 (83.9)	906 (84.0)
Comparison	606	494 (81.6)	501 (82.6)	491 (81.0)	479 (79.0)
% Difference (95% CI)		NA	-1.3 (-7.3 to 4.8)	2.9 (-4.8 to 10.7)	5.0 (-0.4 to 10.4)
P value		NA	.68	.46	.07
LDL-C abnormal					
Pilot	582	199 (34.2)	191 (32.8)	176 (30.3)	201 (34.6)
Comparison	175	60 (34.2)	54 (30.7)	47 (26.9)	62 (35.2)
% Difference (95% CI)		NA	2.1 (-8.7 to 12.8)	3.4 (-11.2 to 18.0)	-0.6 (-22.4 to 21.3)
P value		NA	.72	.63	.97
Nephropathy monitoring					
Pilot	1079	786 (72.8)	842 (78.0)	875 (81.1)	892 (82.7)
Comparison	606	441 (72.8)	440 (72.6)	444 (73.3)	435 (71.7)
% Difference (95% CI)		NA	5.5 (0.5 to 10.5)	7.8 (3.0 to 12.3)	11.0 (5.6 to 16.3)
P value		NA	.03	.002	<.001
Eye examinations					
Pilot	1079	447 (41.4)	507 (47.0)	519 (48.1)	531 (49.2)
Comparison	606	251 (41.4)	261 (43.0)	273 (45.0)	277 (45.7)
% Difference (95% CI)		NA	4.0 (-0.4 to 8.3)	3.1 (-4.8 to 11.0)	3.5 (-3.7 to 10.7)
P value		NA	.07	.45	.33
Asthma appropriate medication, pediatric					
Pilot	603	543 (90.1)	546 (90.5)	535 (88.7)	541 (89.8)
Comparison	820	739 (90.1)	794 (96.8)	813 (99.1)	816 (99.5)
% Difference (95% CI)		NA <sup>b</sup>	-6.4 (-13.4 to 0.7)	-10.4 (-25.2 to 4.4)	-9.7 (-22.4 to 3.1)
P value		NA	.08	.17	.14
Breast cancer screening					
Pilot	4330	2416 (55.8)	2988 (69.0)	3079 (71.1)	3057 (70.6)
Comparison	2804	1565 (55.8)	1890 (67.4)	1971 (70.3)	1943 (69.3)
% Difference (95% CI)		NA	1.6 (-1.4 to 4.6)	0.7 (-3.5 to 5.0)	1.3 (-3.9 to 6.5)
P value		NA	.29	.73	.62
Cervical cancer screening					
Pilot	2549	1700 (66.7)	1876 (73.6)	1998 (78.4)	1917 (75.2)
Comparison	1710	1141 (66.7)	1277 (74.7)	1332 (77.9)	1300 (76.0)
% Difference (95% CI)		NA	-1.1 (-3.9 to 1.7)	0.5 (-3.3 to 4.3)	-0.8 (-6.7 to 5.1)
P value		NA	.43	.79	.79

(continued)



**Table 3. Propensity-Weighted, Adjusted Quality-of-Care Differences Between Pilot and Comparison Practices Among Continuously Enrolled Patients (continued)**

	No. of Eligible Patients	No. (%) <sup>a</sup>			
		Preintervention	Year 1	Year 2	Year 3
Chlamydia screening					
Pilot	521	180 (34.6)	200 (38.3)	226 (43.3)	249 (47.7)
Comparison	521	180 (34.6)	205 (39.3)	247 (47.4)	247 (47.4)
% Difference (95% CI)		NA	-1.0 (-7.0 to 4.9)	-4.2 (-10.2 to 1.9)	0.3 (-5.9 to 6.5)
<i>P</i> value		NA	.74	.18	.92
Colorectal cancer screening					
Pilot	4949	1965 (39.7)	2361 (47.7)	2722 (55.0)	2722 (55.0)
Comparison	3493	1387 (39.7)	1579 (45.2)	1816 (52.0)	1764 (50.5)
% Difference (95% CI)		NA	2.6 (-0.4 to 5.6)	3.1 (-1.0 to 7.1)	4.3 (-3.9 to 12.9)
<i>P</i> value		NA	.09	.14	.30

Abbreviations: LDL-C, low-density lipoprotein cholesterol; NA, not applicable.

<sup>a</sup> Percentage point estimates are propensity-weighted recycled predictions from linear probability models adjusting for practice baseline score, health plan contributing each observation, and whether each patient was in a health maintenance organization at the time of the observation. Frequencies are

calculated from adjusted, weighted percentages based on the denominators for each measure. Differences, CIs, and P values correspond to marginal differences from the linear probability models.

<sup>b</sup> Because of the inclusion of fixed effects for practices, regression models do not estimate preintervention differences between pilot and comparison.

January 1, 2007, limiting the effective study window to January 1, 2007, to May 30, 2011, for analyses of pooled claims data.

Of the 11 quality measures evaluated, pilot participation was significantly associated with greater performance improvement on 1 measure: nephropathy monitoring in diabetes (Table 3). Point estimates suggested improved performance among pilot practices relative to comparison practices for other diabetes measures and for colorectal cancer screening, but these differences were not statistically significant.

Pilot participation was associated with a greater increase in the rate of ambulatory care-sensitive hospitalization, relative to comparison practices, in intervention year 2 (Table 4). There were no other statistically significant differences in measures of utilization, costs of care, or rates of multiple same-year hospitalizations or ED visits (Table 5).

The results of sensitivity analyses were consistent with the primary results with 3 exceptions. First, in models including patients who were not continuously enrolled, pilot participation was statistically significantly associated with better performance for colorectal cancer screening. Second, in models with cross-sectional attribution, pilot participation was statistically significantly associated with worse performance on pediatric asthma appropriate medication use. Third, pilot participation was not statistically significantly associated, in any year, with ambulatory care-sensitive hospitalization rates in models with cross-sectional attribution and in models including patients lacking continuous enrollment.

## Discussion

Despite widespread enthusiasm for the medical home concept, few peer-reviewed publications have found that transforming primary care practices into medical homes (as

defined by common recognition tools and in typical practice settings) produces measurable improvements in the quality and efficiency of care.<sup>6-8</sup> The southeast region of the PACCI, which featured relatively generous financial support from 6 commercial and Medicaid health plans, is to our knowledge the first multipayer pilot in the nation to report results over a 3-year period of transformation. We found that practices participating in the PACCI pilot adopted new structural capabilities and received NCQA certification as medical homes. Our evaluation also suggests that the quality of diabetes care improved, but we found few statistically significant results and no robust associations with utilization or costs.

Our findings differ with prior evaluations of demonstrations in large, integrated delivery systems<sup>14,15,35</sup> and with cross-sectional studies that lacked an intervention.<sup>36,37</sup> However, the southeast PACCI contained ingredients common to many current pilots, including an emphasis on NCQA recognition.<sup>4</sup> Our findings are congruent with those of medical home interventions occurring among small primary care practices, even though the PACCI intervention included more participating practices, occurred over a longer time frame, and featured greater financial support.<sup>11-13,38,39</sup>

Why was the PACCI southeast regional pilot not associated with broad quality improvements, lower utilization, and cost savings? This pilot—the first of the PACCI regions—was focused on quality improvement for chronic conditions and featured early financial rewards for NCQA recognition, possibly distracting from other activities intended to improve the quality and efficiency of care. In subsequent regions, PACCI organizers placed less emphasis on early NCQA recognition so that practices could focus more fully on learning collaborative participation (oral communication with Michael Bailit, MM, Bailit Health Purchasing, November 26, 2010).

Table 4. Propensity-Weighted, Adjusted Differences in Utilization and Costs of Care Between Pilot and Comparison Practices Among Continuously Enrolled Patients (n=39559 Pilot and n=40234 Comparison Patients)

	No. (Rate per 1000 Patients per mo) [95% CI] <sup>a</sup>			
	Preintervention	Year 1	Year 2	Year 3
Hospitalizations, all-cause				
Pilot	479 (12.1) [9.4 to 14.8]	435 (11.0) [7.3 to 14.7]	435 (11.0) [7.4 to 14.6]	427 (10.8) [7.1 to 14.5]
Comparison	489 (12.1) [9.3 to 14.9]	394 (9.8) [7.3 to 12.3]	398 (9.9) [7.4 to 12.4]	386 (9.6) [7.1 to 12.1]
Difference (95% CI) <sup>b</sup>	NA <sup>c</sup>	1.2 (−0.9 to 3.8)	1.1 (−1.1 to 3.9)	1.2 (−1.2 to 4.4)
P value	NA	.30	.36	.36
Hospitalizations, ambulatory care-sensitive				
Pilot	67 (1.7) [1.3 to 2.1]	71 (1.8) [1.4 to 2.2]	83 (2.1) [1.6 to 2.6]	83 (2.1) [1.6 to 2.6]
Comparison	68 (1.7) [1.1 to 2.3]	64 (1.6) [1.1 to 2.1]	68 (1.7) [1.2 to 2.2]	72 (1.8) [1.4 to 2.2]
Difference (95% CI) <sup>b</sup>	NA	0.2 (−0.1 to 0.7)	0.4 (0.1 to 0.8)	0.3 (−0.3 to 1.0)
P value	NA	.20	.007	.33
ED visits, all-cause				
Pilot	1646 (41.6) [31.3 to 51.9]	1839 (46.5) [34.0 to 59.0]	1851 (46.8) [34.2 to 59.4]	1745 (44.1) [31.9 to 56.3]
Comparison	1673 (41.6) [29.7 to 53.5]	1867 (46.4) [34.4 to 58.4]	1854 (46.1) [34.5 to 57.7]	1698 (42.2) [31.9 to 52.5]
Difference (95% CI) <sup>b</sup>	NA	0.1 (−3.2 to 3.8)	0.7 (−3.2 to 5.0)	1.9 (−3.1 to 7.5)
P value	NA	.94	.73	.47
ED visits, ambulatory care-sensitive				
Pilot	1100 (27.8) [19.9 to 35.7]	1187 (30.0) [20.6 to 39.4]	1163 (29.4) [20.0 to 38.8]	1092 (27.6) [18.4 to 36.8]
Comparison	1119 (27.8) [18.7 to 37.0]	1155 (28.7) [19.9 to 37.5]	1123 (27.9) [29.5 to 36.3]	1006 (25.0) [17.5 to 32.5]
Difference (95% CI) <sup>b</sup>	NA	1.3 (−1.4 to 4.3)	1.5 (−2.1 to 5.5)	2.6 (−1.7 to 7.7)
P value	NA	.35	.43	.25
Ambulatory visits, primary care				
Pilot	6496 (164.2) [142.0 to 186.4]	6045 (152.8) [123.0 to 182.6]	5993 (151.5) [120.0 to 183.0]	5811 (146.9) [117.3 to 176.5]
Comparison	6606 (164.2) [144.2 to 184.2]	6047 (150.3) [132.9 to 167.7]	5975 (148.5) [132.2 to 164.8]	5717 (142.1) [127.0 to 157.2]
Difference (95% CI) <sup>b</sup>	NA <sup>c</sup>	2.5 (−0.9 to 5.4)	2.9 (−2.4 to 7.4)	4.8 (−1.7 to 10.5)
P value	NA	.14	.27	.14
Ambulatory visits, specialist				
Pilot	2010 (50.8) [24.8 to 76.8]	2496 (63.1) [34.8 to 91.4]	2623 (66.3) [36.4 to 96.2]	2556 (64.6) [36.0 to 93.2]
Comparison	2044 (50.8) [18.6 to 83.0]	2639 (65.6) [29.1 to 102.1]	2772 (68.9) [29.9 to 107.9]	2740 (68.1) [30.7 to 105.5]
Difference (95% CI) <sup>b</sup>	NA	−2.4 (−3.8 to 1.4)	−2.6 (−4.5 to 1.8)	−3.5 (−6.4 to 3.0)
P value	NA	.57	.21	.40
Total costs of care, \$ <sup>d</sup>				
Pilot	389.0 (304.1 to 474.6)	417.8 (307.5 to 529.7)	440.2 (313.3 to 566.9)	430.3 (302.7 to 556.3)
Comparison	389.0 (317.5 to 458.9)	382.4 (300.0 to 460.1)	407.2 (314.1 to 494.0)	395.2 (303.0 to 480.2)
Difference (95% CI)	NA	35.4 (−7.7 to 78.5)	33.0 (−10.4 to 76.4)	35.1 (−22.3 to 92.5)
P value	NA	.11	.14	.23

Abbreviations: ED, emergency department; NA, not applicable.

<sup>a</sup> Point estimates are propensity-weighted recycled predictions from negative binomial regression models adjusting for baseline utilization rates; patient sex, age, and Charlson comorbidity score; health plan contributing each observation; and whether each patient was in a health maintenance organization at the time of the observation. Frequencies are calculated from adjusted, weighted percentages based on the denominators for each measure. Differences, CIs, and *P* values represent marginal differences from these models.

<sup>b</sup> Difference per 1000 patients per month.

<sup>c</sup> Because of the inclusion of fixed effects for practices, regression models do not estimate preintervention differences between pilot and comparison.

<sup>d</sup> Point estimates and CIs for cost are propensity-weighted recycled predictions from linear models adjusting for baseline costs of care; patient sex, age, and Charlson comorbidity score; health plan contributing each observation; and whether each patient was in a health maintenance organization at the time of the observation. Differences, their CIs, and *P* values correspond to marginal differences from the linear cost models.



**Table 5. Propensity-Weighted, Adjusted Rates of Multiple Hospital and ED Use in Each Year Among Continuously Enrolled Patients Attributed to Pilot and Comparison Practices<sup>a</sup>**

	No. (%) <sup>b</sup>			
	12 mo Prior to Intervention	Year 1	Year 2	Year 3
<b>2 Hospitalizations within year, all-cause</b>				
Pilot	554 (1.4)	561 (1.4)	529 (1.3)	480 (1.2)
Comparison	563 (1.4)	471 (1.2)	504 (1.3)	414 (1.0)
OR (95% CI)	NA <sup>c</sup>	1.22 (0.89-1.68)	1.07 (0.76-1.50)	1.18 (0.84-1.67)
P value	NA	.22	.70	.34
<b>≥3 Hospitalizations within year, all-cause</b>				
Pilot	320 (0.81)	358 (0.91)	385 (0.97)	386 (0.98)
Comparison	325 (0.81)	337 (0.84)	354 (0.88)	353 (0.88)
OR (95% CI)	NA	1.09 (0.83-1.42)	1.12 (0.82-1.51)	1.12 (0.79-1.60)
P value	NA	.54	.48	.52
<b>2 ED visits within year, all-cause</b>				
Pilot	1977 (5.0)	2255 (5.7)	2305 (5.8)	2132 (5.4)
Comparison	2012 (5.0)	2344 (5.8)	2410 (6.0)	2161 (5.4)
OR (95% CI)	NA	1.00 (0.90-1.10)	0.99 (0.89-1.11)	1.01 (0.88-1.17)
P value	NA	.96	.89	.86
<b>≥3 ED visits within year, all-cause</b>				
Pilot	2018 (5.1)	2267 (5.7)	2271 (5.7)	2099 (5.3)
Comparison	2052 (5.1)	2616 (6.5)	2562 (6.4)	2240 (5.6)
OR (95% CI)	NA	0.85 (0.71-1.02)	0.88 (0.73-1.06)	0.93 (0.74-1.17)
P value	NA	.09	.17	.54

Abbreviations: ED, emergency department; NA, not applicable; OR, odds ratio.

<sup>a</sup> The number of patients contributing data from pilot practices was 39 559 and from comparison practices, 40 234, in the preintervention period; these patients had continuous enrollment in their health plan during the study period.

<sup>b</sup> Point estimates are propensity-weighted recycled predictions from logistic regression models adjusting for baseline utilization rates; patient sex, age, and Charlson comorbidity score; health plan contributing each observation; and whether each patient was in a health maintenance organization at the time of the observation. Frequencies are calculated from adjusted, weighted percentages based on the denominators for each measure. Odds ratios, CIs, and *P* values reflect marginal differences between pilot and comparison in each intervention year.

<sup>c</sup> Because of the inclusion of fixed effects for practices, regression models do not estimate preintervention differences between pilot and comparison.

In addition, southeast PACCI pilot practices had neither direct incentives to contain costs nor feedback on their patients' utilization of care. Possibly as a consequence of these features of pilot design, we found that few pilot practices increased their night and weekend access capabilities, which could, in theory, have produced short-term savings by offering patients an alternative to more expensive sites of care (such as hospital emergency departments).

Several reasons may explain the limited (or absent) changes in quality, utilization, and costs of care that we observed, despite structural transformation among pilot practices. First, pilot practices were volunteers and may have been more quality-conscious than other practices, performing closer to their optimal levels at baseline. If so, "ceiling effects" resulting from near-optimal performance would imply that an average practice developing a medical home structure might show greater improvement than what we observed. Therefore, our findings may not generalize to other medical home interventions. Second, the structural survey response rate among comparison practices was low, so we cannot tell whether comparison practices were also transforming during the pilot (eg, due to federal incentives to adopt EHRs). Simultaneous transformation would weaken the ability of pilot practices to differentiate themselves from comparison practices. Third, prior cross-

sectional research suggests that relationships between structural capabilities, NCQA recognition, and performance on measures of quality and utilization are modest.<sup>40-42</sup> The elements of practice transformation necessary to produce desired changes in patient care may be different from the capabilities assessed commonly by research surveys and certification tools.

Our study has limitations. First, pilot and comparison practices were not matched perfectly. Although propensity weighting and multiple regression can account for observed differences, unobserved differences could have introduced confounding. Second, failure to find statistically significant results for most diabetes measures may have resulted from insufficient power to detect performance improvement differences smaller than approximately 8 percentage points. Third, the baseline structural survey was retrospective, with potential respondent recall error. Fourth, we were unable to examine changes in patient experience.

## Conclusions

One of the first, largest, and longest-running multipayer medical home pilots in the United States, in which participating practices adopted new structural capabilities and received NCQA

certification, was associated with limited improvements in quality and was not associated with reductions in utilization of hospital, emergency department, or ambulatory care ser-

vices or total costs of care over 3 years. These findings suggest that medical home interventions may need further refinement.

## ARTICLE INFORMATION

**Author Affiliations:** RAND Corporation, Boston, Massachusetts (Friedberg, Schneider); Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts (Friedberg, Schneider); Department of Medicine, Harvard Medical School, Boston, Massachusetts (Friedberg, Schneider); Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts (Schneider, Rosenthal); Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania (Volpp, Werner); Center for Health Incentives and Behavioral Economics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia (Volpp); Division of General Internal Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia (Volpp, Werner); Department of Health Care Management, Wharton Business School, Philadelphia, Pennsylvania (Volpp); Penn Medicine Center for Health Care Innovation, Philadelphia, Pennsylvania (Volpp).

**Author Contributions:** Drs Friedberg and Werner had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Friedberg, Schneider, Volpp, Werner.

**Acquisition of data:** Friedberg, Schneider, Werner.

**Analysis and interpretation of data:** Friedberg, Schneider, Rosenthal, Werner.

**Drafting of the manuscript:** Friedberg, Schneider. **Critical revision of the manuscript for important intellectual content:** Schneider, Rosenthal, Volpp, Werner.

**Statistical analysis:** Friedberg, Werner.

**Obtained funding:** Friedberg, Schneider, Volpp, Werner.

**Administrative, technical, and material support:** Werner.

**Study supervision:** Friedberg, Schneider, Volpp, Werner.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Friedberg reported having received compensation from the US Department of Veterans Affairs for consultation related to the medical home model and research support from the Patient-Centered Outcomes Research Institute via subcontract to the National Committee for Quality Assurance. Dr Volpp reported having received compensation as a consultant from CVS Caremark and VALHealth and having grants pending with CVS Caremark, Humana, Horizon Blue Cross Blue Shield, Weight Watchers, and Discovery (South Africa). Dr Werner reported having received grants or funding from the Veterans Health Administration, Horizon, and Healthcare Innovation. No other disclosures were reported.

**Funding/Support:** This study was sponsored by the Commonwealth Fund and Aetna.

**Role of the Sponsors:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data;

preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The views presented here are those of the authors and not necessarily those of Aetna, its directors, officers, or staff.

**Additional Contributions:** We gratefully acknowledge Aaron Kofner, MA, MS (RAND), Scott Ashwood, PhD (RAND), Scot Hickey, MA (RAND), Katharine Lauderdale, BA (RAND), Wei Chen, MS (University of Pennsylvania), and Jingsan Zhu, MS, MBA (University of Pennsylvania), for assistance with programming and data management; Claude Setodji, PhD (RAND), for statistical consultation; and Marcela Myers, MD (Commonwealth of Pennsylvania), and Michael Bailit, MM (Bailit Health Purchasing), for providing data on pilot bonus payments and NCQA recognition levels and facilitating other data collection. Mr Kofner, Dr Ashwood, Mr Hickey, Ms Lauderdale, Mr Chen, Mr Zhu, and Dr Setodji received compensation for their roles in the study.

**Correction:** This article was corrected online February 25, 2014, for errors in Table 2.

## REFERENCES

1. Joint principles of the patient-centered medical home [March 2007]. American Academy of Family Physicians, American Academy of Pediatrics, American College of Physicians, American Osteopathic Association. [http://www.acponline.org/running\\_practice/delivery\\_and\\_payment\\_models/pcmh/demonstrations/jointprinc\\_05\\_17.pdf](http://www.acponline.org/running_practice/delivery_and_payment_models/pcmh/demonstrations/jointprinc_05_17.pdf). Accessed January 5, 2014.
2. Statements of support. Patient-Centered Primary Care Collaborative. <http://www.pcpcc.net/content/statements-support>. Accessed January 5, 2014.
3. Friedberg MW, Lai DJ, Hussey PS, Schneider EC. A guide to the medical home as a practice-level intervention. *Am J Manag Care*. 2009;15(10)(suppl):S291-S299.
4. Bitton A, Martin C, Landon BE. A nationwide survey of patient centered medical home demonstration projects. *J Gen Intern Med*. 2010;25(6):584-592.
5. Patient centered medical home resource center: catalogue of federal PCMH activities. Agency for Healthcare Research and Quality. <http://pcmh.ahrq.gov/page/federal-pcmh-activities>. Accessed January 5, 2014.
6. Peikes D, Zutshi A, Genevro JL, Parchman ML, Meyers DS. Early evaluations of the medical home: building on a promising start. *Am J Manag Care*. 2012;18(2):105-116.
7. Jackson GL, Powers BJ, Chatterjee R, et al. The patient-centered medical home: a systematic review. *Ann Intern Med*. 2013;158(3):169-178.
8. Hoff T, Weller W, DePuccio M. The patient-centered medical home: a review of recent research. *Med Care Res Rev*. 2012;69(6):619-644.
9. Crabtree BF, Nutting PA, Miller WL, Stange KC, Stewart EE, Jaén CR. Summary of the National Demonstration Project and recommendations for the patient-centered medical home. *Ann Fam Med*. 2010;8(suppl 1):S80-S90, S92.
10. Boulton C, Reider L, Leff B, et al. The effect of guided care teams on the use of health services: results from a cluster-randomized controlled trial. *Arch Intern Med*. 2011;171(5):460-466.
11. Werner RM, Duggan M, Duey K, Zhu J, Stuart EA. The patient-centered medical home: an evaluation of a single private payer demonstration in New Jersey. *Med Care*. 2013;51(6):487-493.
12. Fifield J, Forrest DD, Burleson JA, Martin-Peele M, Gillespie W. Quality and efficiency in small practices transitioning to patient centered medical homes: a randomized trial. *J Gen Intern Med*. 2013;28(6):778-786.
13. Rosenthal MB, Friedberg MW, Singer SJ, Eastman D, Li Z, Schneider EC. Effect of a multipayer patient-centered medical home on health care utilization and quality: the Rhode Island chronic care sustainability initiative pilot program. *JAMA Intern Med*. 2013;173(20):1907-1913.
14. Reid RJ, Coleman K, Johnson EA, et al. The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. *Health Aff (Millwood)*. 2010;29(5):835-843.
15. Gilfillan RJ, Tomcavage J, Rosenthal MB, et al. Value and the medical home: effects of transformed primary care. *Am J Manag Care*. 2010;16(8):607-614.
16. Gabbay RA, Bailit MH, Mauger DT, Wagner EH, Siminerio L. Multipayer patient-centered medical home implementation guided by the chronic care model. *Jt Comm J Qual Patient Saf*. 2011;37(6):265-273.
17. Gabbay RA, Friedberg MW, Miller-Day M, Cronholm PF, Adelman A, Schneider EC. A positive deviance approach to understanding key features to improving diabetes care in the medical home. *Ann Fam Med*. 2013;11(suppl 1):S99-S107.
18. The breakthrough series: IHI's collaborative model for achieving breakthrough improvement. Institute for Healthcare Improvement. <http://www.ihi.org/resources/Pages/IHIWhitePapers/TheBreakthroughSeriesIHICollaborativeModelforAchievingBreakthroughImprovement.aspx>. Accessed January 5, 2014.
19. Improving performance in practice. American Board of Medical Specialties. <http://www.ipiprogram.org>. Accessed January 5, 2014.
20. National Committee for Quality Assurance. *Standards and Guidelines for Physician Practice Connections—Patient-Centered Medical Home (PPC-PCMH)*. Washington, DC: National Committee for Quality Assurance; 2008.
21. Friedberg MW, Safran DG, Coltin KL, Dresser M, Schneider EC. Readiness for the patient-centered medical home: structural capabilities of Massachusetts primary care practices. *J Gen Intern Med*. 2009;24(2):162-169.
22. Rosenthal MB, Abrams MK, Bitton A. Recommended core measures for evaluating the patient-centered medical home: cost, utilization, and clinical quality. Commonwealth Fund. [http://www.commonwealthfund.org/-/media/Files/Publications/Data%20Brief/2012/1601\\_Rosenthal](http://www.commonwealthfund.org/-/media/Files/Publications/Data%20Brief/2012/1601_Rosenthal)

\_recommended\_core\_measures\_PCMH\_v2.pdf. Accessed January 5, 2014.

23. Rosenthal MB, Beckman HB, Forrest DD, Huang ES, Landon BE, Lewis S. Will the patient-centered medical home improve efficiency and reduce costs of care? a measurement and research agenda. *Med Care Res Rev*. 2010;67(4):476-484.
24. Optum normalized pricing for health care analytics. Optum. <http://www.optuminsight.com>. Accessed February 4, 2014.
25. McWilliams JM, Chernew ME, Zaslavsky AM, Landon BE. Post-acute care and ACOs: who will be accountable? *Health Serv Res*. 2013;48(4):1526-1538.
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1):41-55.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.
28. Song Z, Safran DG, Landon BE, et al. Health care spending and quality in year 1 of the alternative quality contract. *N Engl J Med*. 2011;365(10):909-918.
29. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? comparing methods of modeling Medicare expenditures. *J Health Econ*. 2004;23(3):525-542.
30. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. *Biometrika*. 1986;73:13-22.
31. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*. 1986;42(1):121-130.
32. Graubard BI, Korn EL. Predictive margins with survey data. *Biometrics*. 1999;55(2):652-659.
33. Setodji CM, Scheuner M, Pankow JS, Blumenthal RS, Chen H, Keeler E. A graphical method for assessing risk factor threshold values using the generalized additive model: the multi-ethnic study of atherosclerosis. *Health Serv Outcomes Res Methodol*. 2012;12(1):62-79.
34. Peikes D, Dale S, Lundquist E, Genevro J, Meyers D. Building the evidence base for the medical home: what sample and sample size do studies need? Agency for Healthcare Research and Quality. <http://pcmh.ahrq.gov/page/building-evidence-base-medical-home-what-sample-and-sample-size-do-studies-need>. Accessed February 4, 2014.
35. Reid RJ, Fishman PA, Yu O, et al. Patient-centered medical home demonstration: a prospective, quasi-experimental, before and after evaluation. *Am J Manag Care*. 2009;15(9):e71-e87.
36. Diedhiou A, Probst JC, Hardin JW, Martin AB, Xirasagar S. Relationship between presence of a reported medical home and emergency department use among children with asthma. *Med Care Res Rev*. 2010;67(4):450-475.
37. Roby DH, Pourat N, Pirritano MJ, et al. Impact of patient-centered medical home assignment on emergency room visits among uninsured patients in a county health system. *Med Care Res Rev*. 2010;67(4):412-430.
38. Jaén CR, Ferrer RL, Miller WL, et al. Patient outcomes at 26 months in the patient-centered medical home National Demonstration Project. *Ann Fam Med*. 2010;8(suppl 1):S57-S67.
39. Nutting PA, Miller WL, Crabtree BF, Jaen CR, Stewart EE, Stange KC. Initial lessons from the first national demonstration project on practice transformation to a patient-centered medical home. *Ann Fam Med*. 2009;7(3):254-260.
40. Friedberg MW, Coltin KL, Safran DG, Dresser M, Zaslavsky AM, Schneider EC. Associations between structural capabilities of primary care practices and performance on selected quality measures. *Ann Intern Med*. 2009;151(7):456-463.
41. Flottemesch TJ, Anderson LH, Solberg LI, Fontaine P, Asche SE. Patient-centered medical home cost reductions limited to complex patients. *Am J Manag Care*. 2012;18(11):677-686.
42. Clarke RM, Tseng CH, Brook RH, Brown AF. Tool used to assess how well community health centers function as medical homes may be flawed. *Health Aff (Millwood)*. 2012;31(3):627-635.